Today: 20 March 2026
AMD stock price rises before the bell even as tariff jitters hit futures — what to watch next
20 January 2026
1 min read

AMD stock price rises before the bell even as tariff jitters hit futures — what to watch next

New York, Jan 20, 2026, 05:22 ET — Premarket

  • AMD gains roughly 1.7% in early trading, reaching $231.83
  • U.S. index futures dip amid renewed concerns over tariff threats related to Greenland
  • Upcoming triggers include Intel’s earnings on Jan. 22 and AMD’s report on Feb. 3

Advanced Micro Devices shares climbed 1.7% to $231.83 in premarket trading Tuesday, after closing the previous session at $227.88.

The early dip unfolded amid a weaker backdrop. S&P 500 and Nasdaq futures fell over 1% after U.S. President Donald Trump revived tariff threats against European countries connected to his bid for Greenland, sparking talk of a “Sell America” trade—where investors offload U.S. stocks, the dollar, and Treasuries—as bond yields edged higher. Kyle Rodda, senior market analyst at Capital.com, said hopes remain that tensions might be “self-limiting,” but cautioned about “a potentially disruptive standoff” with Europe. MUFG’s Henry Cook added that tariff uncertainty could persist at “elevated” levels even if hostilities ease. Reuters

Trump announced plans to slap an extra 10% tariff starting Feb. 1 on imports from Denmark, Norway, Sweden, France, Germany, the Netherlands, Finland, and Britain. If no Greenland deal is struck by June 1, those levies could jump to 25%. “It’s highly likely that the White House will use the threat of tariffs consistently,” noted George Lagarias, chief economist at Forvis Mazars. Reuters

Semiconductor stocks showed mixed moves early Tuesday. Nvidia slipped 0.5% in premarket action, Intel dropped 2.8%, but the iShares Semiconductor ETF climbed 1.6%.

For AMD, the key issue now is whether a risk-off mood will drag down tech multiples more widely — stocks priced on future growth typically take the hit first when rates climb and news turns negative.

Advanced Micro Devices, Inc. will release its fiscal fourth-quarter and full-year 2025 results on Tuesday, Feb. 3, after markets close. The company plans a conference call at 5:00 p.m. EST that day. Additionally, AMD’s CTO Mark Papermaster is set to speak at Morgan Stanley’s Technology, Media & Telecom Conference on March 3. Advanced Micro Devices, Inc.

Intel is up next, scheduled to unveil its Q4 and full-year 2025 earnings on Thursday, Jan. 22, after the market closes. Intel

Investors are tuning in for any shifts in the data center outlook, where AMD pushes its EPYC server CPUs and Instinct “AI accelerators” — specialized chips designed for training and running AI models — as it battles Nvidia for market share.

Tariffs remain a wild card. Just the threat of new duties can halt buying decisions across global hardware supply chains. Chipmakers face pressure when customers demand lower prices or costs spike unexpectedly.

AMD’s next big moment arrives Feb. 3, when it reports earnings and holds a Q&A after the market closes. Until then, expect the stock to bounce on two volatile factors: tariff news out of Washington and early tech earnings cues, beginning with Intel’s report on Jan. 22.

Stock Market Today

  • Ocugen's Gene-Agnostic Eye Therapy Could Transform Retinal Drug Development
    March 20, 2026, 9:31 AM EDT. Ocugen (OCGN) is advancing a modifier gene therapy platform aimed at treating inherited retinal diseases broadly, rather than targeting single genetic mutations. This gene-agnostic approach could benefit patients with diverse mutations, addressing limitations of existing treatments like the sole approved retinitis pigmentosa therapy, which targets only 1-2% of patients. Ocugen's lead candidate, OCU400, aims for a one-time subretinal injection potentially effective across 98-99% of retinitis pigmentosa cases. With phase III enrollment completed and a planned rolling filing in Q3 2026, OCGN's upcoming data and regulatory milestones are critical inflection points. Their strategy extends to other conditions, such as Stargardt disease with OCU410ST, emphasizing broad mutation coverage in retinal therapy development.
Goldman holds $655 Microsoft target as AI data-center power costs loom before earnings
Previous Story

Goldman holds $655 Microsoft target as AI data-center power costs loom before earnings

Alphabet stock slips before the open as Greenland tariff threat rattles big tech
Next Story

Alphabet stock slips before the open as Greenland tariff threat rattles big tech

Go toTop